Journal article

Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?

Richard J MacIsaac

Diabetes Therapy | SPRINGER HEIDELBERG | Published : 2020


The glucagon-like peptide 1 receptor agonist (GLP-1RA) dulaglutide has many characteristics to recommend it both as a second-line agent and as an alternative to or in combination with insulin. This commentary summarises recent updates to diabetes management guidelines regarding the use of GLP-1RAs such as dulaglutide, both as a second-line agent and as a first-line injectable agent in type 2 diabetes (T2D). It also examines how the Assessment of Weekly AdministRation of LY2189265 [dulaglutide] in Diabetes (AWARD) studies with dulaglutide and insulin may help to guide clinical practice for the use of dulaglutide as an alternative to basal insulin or in combination with insulin.Individualising..

View full abstract


Funding Acknowledgements

This article and the journals' Rapid Service Fee were funded by Eli Lilly Australia. The author had full access to the articles reviewed in this manuscript and takes complete responsibility for the integrity and accuracy of this manuscript.